Supriya Lifescience MD Satish Wagh and Director Saloni Wagh on Q1 Results, Profits, and Future Expansion | Satish Wagh, Chairman, Supriya Lifescience Limited. 00:10:00
Supriya Lifescience MD Satish Wagh and Director Saloni Wagh discuss the company's Q1 results, reporting a profit growth from ₹63 crore in FY19 to ₹70 crore in FY22. They provide valuable insights into the future of the export market, which accounts for 80% of Supriya Lifescience's revenue. The company has a strategic Capex plan of ₹30 crore over the next two years to drive further growth and expansion.
